Having experienced a plethora of myriad drug and treatment testing trials since decades, cancer gene therapy market has recently witnessed the discovery of a unique test that may help reduce the mortality rate of patients afflicted with prostate cancer. As per reports, the medical research community has discovered 54 genetic markers that would predispose men to suffering from the deadliest form of prostate cancer. Currently, these tests are priced at GBP 100.
Sources state that this specific study that may revolutionize cancer gene therapy industry had been published in the BMJ, and contributes to the development of a prediction tool. Reportedly, this tool has been developed via the analysis of more than 200,000 gene variants from over 30,000 men, in order to find the ones that are most accurately susceptible to be diagnosed with prostate cancer. For the record, one in eight men are likely to develop prostate cancer during their lifetimes. This estimate may have been the inspiration for scientists to come up with such a tool that would gain supremacy in the entire healthcare and medical devices industry.
As per reports, this tool has been tested clinically on more than 6,000 men. The tool apparently detected that the men who fell among the top 2% of patients have three times the possibility of developing this type of cancer. This discovery undeniably, would help to closely monitor the men at possible risk, target them for screening, and save a considerable percentage of patients from needless tests, biopsies and treatment.
One of the researchers, Dr. Tyler Seibert had been quoted stating that the results of this study is likely to guide medical professionals for improved diagnosis and male patients to decide if a screening would be necessary.
For the record, in UK alone, about 47,000 men are diagnosed with prostate cancer annually. The emergence of this new risk tool is thus likely to provide a boost to Europe cancer gene therapy market, given the growing prevalence of prostate cancer across European countries, as per analysts.
